NeurOptics

Executive Summary

NeurOptics is a US-based medical device company specializing in automated pupillometry technology. Its flagship product, the NPi-300 Pupillometer, provides objective and quantitative pupil measurements, replacing subjective manual assessments in critical care, neurology, neurosurgery, and emergency medicine. Founded in 2004 and headquartered in Laguna Hills, CA, the company has established itself as a leader in transforming pupillary assessment into a standardized vital sign. By enabling early and accurate detection of neurological changes, NeurOptics aims to improve patient outcomes, particularly in settings where prompt intervention is crucial. The NPi-300 is commercially available and has been adopted in hospitals worldwide. However, as a private company without disclosed funding or valuation, its growth trajectory is less visible. Future opportunities may include expanding into new clinical indications, developing next-generation wearable or AI-enhanced devices, and pursuing partnerships to broaden market access. The company's core strength lies in its proprietary technology and established clinical utility.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for NPi-300+ next-gen model with AI- based interpretation70% success
• Q2 2026Publication of multicenter study validating NPi for early detection of stroke60% success
• Q4 2026Strategic partnership with a major hospital network for system-wide deployment50% success